Olema Oncology
Kristin Lanzi serves as Vice President of Information Technology at Olema Oncology, bringing more than 20 years of strong IT biotechnology and pharmaceutical experience with deep strategic and execution capabilities in both pre- and post-commercial environments. Prior to joining Olema, Ms. Lanzi served as Vice President of IT for Iovance Biotherapeutics, where she scaled the organization to support the addition of a commercial workforce, as well as systems and technology for a new manufacturing site. Earlier in her career, Ms. Lanzi held leadership roles of increasing responsibility at key global biotechnology and pharmaceutical companies including Genentech, Roche, Achaogen, and Medivation (now Pfizer). She held pivotal strategic positions at these organizations to rapidly scale IT in order to support growth and compliance. Ms. Lanzi holds a bachelor’s degree in Business and Political Science from California Polytechnic State University, San Luis Obispo.
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.